

Amendments to the Claim:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) Antimicrobial composition comprising lysozyme and synthetically glycosylated immunoglobulins directed towards antigens on the surface of Gram negative bacteria, wherein said synthetically glycosylated immunoglobulins have been produced by dissolving ~~parental~~ non-synthetically glycosylated immunoglobulins in a solution comprising disaccharide or monosaccharide under conditions resulting in synthetic glycosylation of said parental immunoglobulins, and wherein said antimicrobial composition has increased bactericidal activity at least in part as a result of said synthetic glycosylation.

2. (Original) Antimicrobial composition according to claim 1 for local use on mucosal membranes and/or skin.

3. (Original) Antimicrobial composition according to claim 1, wherein said glycosylated immunoglobulins have affinity to Gram negative bacteria.

4. (Original) Antimicrobial composition according to claim 3, wherein the Gram negative bacteria are rods and/or cocci or a combination thereof.

5. (Original) Antimicrobial composition according to claim 1, wherein said glycosylated immunoglobulins have affinity to Gram positive bacteria.

6. (Original) Antimicrobial composition according to claim 1, wherein said glycosylated immunoglobulins have affinity to viruses.

7. (Original) Antimicrobial composition according to claim 3, wherein the glycosylated immunoglobulins have affinity to antigen determinants on the cell wall of Gram negative bacteria.

8. (Original) Antimicrobial composition according to

claim 1, wherein the glycosylated immunoglobulins are of monoclonal or polyclonal origin.

9. (Original) Antimicrobial composition according to claim 1, wherein the glycosylated immunoglobulins are of monoclonal and/or polyclonal origin or a combination thereof.

10. (Original) Antimicrobial composition according to claim 1, wherein the glycosylated immunoglobulins are of the classes IgM, IgG, IgY, IgA or dimer IgA.

11. (Original) Antimicrobial composition according to claim 1, wherein the glycosylated immunoglobulins are of the IgG class and/or the IgY class.

12. (Previously Presented) Antimicrobial composition according to claim 1, wherein the glycosylated immunoglobulins are resistant to bacterial proteases and/or pancreatic proteases.

13. (Previously Presented) Antimicrobial composition according to claim 1, wherein the glycosylated immunoglobulins are resistant to papain and/or bromelain and/or pepsin.

14. (Previously Presented) Antimicrobial composition according to claim 1, wherein the glycosylated immunoglobulins are resistant to acidic conditions associated with gastric juice.

15. (Previously Presented) Antimicrobial composition according to claim 1, wherein the glycosylated immunoglobulins have reduced complement fixation activity relative to said parental immunoglobulins.

16. (Currently Amended) Antimicrobial composition according to claim 1, wherein the parental non-synthetically glycosylated immunoglobulins were obtained from a biological fluid.

17. (Currently Amended) Antimicrobial composition according to claim 1, wherein the parental non-synthetically glycosylated immunoglobulins were obtained from milk, colostrum, yolk or a combination thereof.

18. (Currently Amended) Antimicrobial composition

according to claim 1, wherein the parental non-synthetically glycosylated immunoglobulins originate from immunized animals and/or non-immunized animals.

19. (Original) Antimicrobial composition according to claim 1, wherein the lysozyme is native or conjugated.

20. (Previously Presented) Antimicrobial composition according to claim 19, wherein the lysozyme is conjugated to a monosaccharide.

21. (Original) Antimicrobial composition according to claim 20, wherein the lysozyme is conjugated to mannose.

22. (Original) Antimicrobial composition according to claim 1, wherein the lysozyme is extracted from egg white.

23. (Previously Presented) Antimicrobial composition according to claim 1, wherein the antimicrobial composition is selected from the group consisting of a cream, an ointment, a gel, a wet tissue, a chewable tablet, a lozenge and a chewing gum.

24. (Original) Antimicrobial composition according to claim 1, wherein the antimicrobial composition is in the form of a lozenge or chewing gum.

25. (Previously Presented) Antimicrobial composition according to claim 1, wherein said lysozyme constitutes in the range of 0.05% to 10% by weight of the composition.

26. (Previously Presented) Antimicrobial composition according to claim 1, wherein said glycosylated immunoglobulins constitute in the range of 0.1% to 10% by weight of the composition.

27-30. (Cancelled)

31. (Currently Amended) Antimicrobial composition according to claim 1, wherein the parental non-synthetically glycosylated immunoglobulins are selected from the group consisting of native naturally glycosylated immunoglobulins, native deglycosylated immunoglobulins, recombinant deglycosylated immunoglobulins and recombinant unglycosylated immunoglobulins.

32. (Currently Amended) Antimicrobial composition according to claim 1, wherein the synthetically glycosylated immunoglobulins have prolonged half-life compared to said ~~parental non-synthetically glycosylated~~ immunoglobulins.